Please use this identifier to cite or link to this item:
https://hdl.handle.net/10419/18957
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Brekke, Kurt R. | en |
dc.contributor.author | Kuhn, Michael | en |
dc.date.accessioned | 2009-01-28T15:54:04Z | - |
dc.date.available | 2009-01-28T15:54:04Z | - |
dc.date.issued | 2005 | - |
dc.identifier.uri | http://hdl.handle.net/10419/18957 | - |
dc.description.abstract | We study effects of direct-to-consumer advertising (DTCA) in the prescription drug market.There are two pharmaceutical firms providing horizontally differentiated (branded) drugs.Patients differ in their susceptibility to the drugs. If DTCA is allowed, this can be employed toinduce (additional) patient visits. Physicians perfectly observe the patients' type (of illness),but rely on information to prescribe the correct drug. Drug information is conveyed bymarketing (detailing), creating a captive and a selective segment of physicians. First, we showthat detailing, DTCA and price (if not regulated) are complementary strategies for the firms.Thus, allowing DTCA induces more detailing and higher prices. Second, firms benefit fromDTCA if detailing competition is not too fierce, which is true if investing in detailing issufficiently costly. Otherwise, firms are better off with a ban on DTCA. Finally, DTCA tendsto lower welfare if insurance is generous (low copayments) and/or price regulation is lenient.The desirability of DTCA also depends on whether or not the regulator is concerned withfirms' profit. | en |
dc.language.iso | eng | en |
dc.publisher | |aCenter for Economic Studies and ifo Institute (CESifo) |cMunich | en |
dc.relation.ispartofseries | |aCESifo Working Paper |x1493 | en |
dc.subject.jel | I11 | en |
dc.subject.jel | M37 | en |
dc.subject.jel | L65 | en |
dc.subject.jel | L13 | en |
dc.subject.ddc | 330 | en |
dc.subject.keyword | marketing | en |
dc.subject.keyword | pharmaceuticals | en |
dc.subject.keyword | oligopoly | en |
dc.subject.stw | Werbung | en |
dc.subject.stw | Pharmazeutisches Produkt | en |
dc.subject.stw | Oligopol | en |
dc.title | Direct to consumer advertising in pharmaceutical markets | - |
dc.type | Working Paper | en |
dc.identifier.ppn | 50046863X | en |
dc.rights | http://www.econstor.eu/dspace/Nutzungsbedingungen | en |
Files in This Item:
Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.